We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Elite Seeks RLD Exception in Effort to Return Lodrane to Market
Elite Seeks RLD Exception in Effort to Return Lodrane to Market
June 18, 2013
Elite Pharmaceuticals filed a citizen petition with the FDA this month requesting permission to reference an approved ANDA product as the reference listed drug (RLD), in its latest effort to bring its discontinued extended release Lodrane products back to the market.